Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.48 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29422008 | 0.97 | APLNR (0.53) | APLNRNTSR1NTSR2OPRD1OPRM1 | |
| SCHEMBL29421924 | 0.97 | APLNR (0.49) | APLNRNTSR1NTSR2OPRD1REN | |
| SCHEMBL22380749 | 0.94 | APLNR (0.52) | APLNRNTSR1NTSR2OPRD1REN | |
| SCHEMBL30933143 | 0.93 | APLNR (0.53) | APLNRNTSR1OPRD1REN | |
| SCHEMBL30933156 | 0.93 | APLNR (0.53) | APLNRNTSR1OPRD1REN | |
| SCHEMBL30170451 | 0.93 | APLNR (0.53) | APLNRNTSR1OPRD1REN | |
| SCHEMBL30933096 | 0.92 | APLNR (0.51) | APLNRNTSR1NTSR2OPRD1REN | |
| SCHEMBL30933116 | 0.91 | APLNR (0.51) | APLNROPRD1RENOPRM1OPRK1 | |
| SCHEMBL29421949 | 0.91 | APLNR (0.49) | APLNRNTSR1NTSR2OPRD1F2 | |
| SCHEMBL30933099 | 0.91 | APLNR (0.51) | APLNROPRD1RENOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483959-A2 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2025-01-01 | — | — | EP | disclosed |
| EP-3974441-B1 | PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-10-24 | — | — | US | disclosed |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-3974441-A1 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | APLNR 228/4885NTSR1 215/4885NTSR2 194/4885 |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | APLNR 228/4885NTSR1 215/4885NTSR2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.